Expression Analysis of Cancer-Testis Genes in Prostate Cancer Reveals Candidates for Immunotherapy

Faramarzi, Sepideh; Ghafouri‐Fard, Soudeh

doi:10.2217/imt-2017-0083

Cited by 8 publications

(3 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The benefit of the popularity of PSA screening is that PCa can be detected at an early stage that led to a decrease in mortality rates [ 18 ]. However, PCa has an unpredictable clinical outcome, such as variable biochemical recurrence time, because it is a biologically heterogeneous and multifocal disease [ 19 – 22 ]. Meanwhile, the underlying mechanism of its carcinogenesis and cancer progression have not been totally explored.…”

Section: Discussionmentioning

confidence: 99%

High Expression of KIF22/Kinesin-Like DNA Binding Protein (Kid) as a Poor Prognostic Factor in Prostate Cancer Patients

et al. 2018

View full text Add to dashboard Cite

BackgroundKid (kinesin-like DNA binding protein), a member of microtubule-dependent molecular motor proteins, also known as KIF22, is reported to be associated with carcinogenesis and cancer progression in different types of malignant tumor, but the biologic behavior and clinical outcome of KIF22 in prostate cancer (PCa) has not been well studied. This study aimed to analyze the association between KIF22 and clinical outcome in PCa patients.Material/MethodsThe expression of KIF22 in tumor specimens compared with paired paracancerous tissue from 114 patients undergoing radical prostatectomy was detected by immunohistochemistry; results were verified using The Cancer Genome Atlas (TCGA) database. Subsequently, the relationship between KIF22 expression and clinical prognosis of PCa patients was then statistically analyzed.ResultsBoth immunohistochemistry and database analysis showed that KIF22 was obviously overexpressed in PCa tissues compared with paracancerous tissue. The overexpression of KIF22 at the protein level was significantly related to higher clinical stage (P=0.025), Gleason score (P=0.002), seminal vesicle invasion (P=0.007), and lymph node metastasis (P=0.009). Furthermore, with the overexpression of KIF22 mRNA level in PCa patients, the oncological prognosis of PCa patients was much poorer.ConclusionsHigh-level expression of KIF22 was related to both tumor progression and adverse clinical outcome. For this reason, KIF22 may become a potential prognostic factor for PCa.

show abstract

Section: Discussionmentioning

confidence: 99%

High Expression of KIF22/Kinesin-Like DNA Binding Protein (Kid) as a Poor Prognostic Factor in Prostate Cancer Patients

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In the early 1990s, MAGE-1 was rst reported to elicit a spontaneous cytotoxic T lymphocyte (CTL) response in the autologous melanoma patient (van der Bruggen et al 1991;Traversari et al 1992). In recent decades, some oncogenic CTA-targeted immunotherapies-including CTA-targeted antibodies, vaccines, and chimeric antigen receptor-modi ed T cells (CAR-T)-have experienced signi cant progress and these have been applied to clinical treatments (Siliņa et al 2011;Faramarzi et al 2017). Novel immunotherapies have recently provided emerging therapeutic perspectives for advanced or aggressive lung cancer.…”

Section: Introductionmentioning

confidence: 99%

Identification of a Cancer Testis Antigen-Associated Six-Gene Signature in Lung Adenocarcinoma for the Prediction of Survival and Response to Immune-Checkpoint Inhibitors

Huang

Zhao

Chen

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Lung cancer is a leading cause of cancer-related deaths, with lung adenocarcinoma (LUAD) being one of the major types of lung cancer. A limited number of studies have revealed that cancer testis antigens (CTAs) could serve as prognostic indicators for LUAD patients. Methods In this bioinformatics study, we constructed a novel CTA-related gene signature that predicted survival and responses to immune-checkpoint inhibitors (ICIs) in patients with LUAD, and exploited univariate and Lasso-Cox regression analyses to evaluate the mechanisms underlying the signature’s prognostic capability. Immune cell infiltration, tumor mutation burden (TMB), and immunophenoscores (IPSs) related to the prognostic signature in LUAD with different risk scores were thoroughly explored. Results Our prognostic signature was based upon six CTAs, and multivariate analysis showed that the six-CTA signature was an independent prognostic factor in overall survival for patients with LUAD. Memory resting CD4 T cells, monocytes, dendritic resting cells, and resting mast cells were elevated in the six-CTA signature high-risk group, and M0 macrophages and activated mast cells were reduced relative to the low-risk group. The six-CTA signature low-risk group possessed a higher IPS, and was more sensitive to an immune-checkpoint inhibitor (ICI)—representing a more immunogenic phenotype. Conclusion In summary, we herein established a six-CTA prognostic signature for predicting survival in patients with LUAD and their potential responses to immunotherapy.

show abstract

“…As a tumor suppressor, FAM46C functions in the regulation of cell proliferation, apoptosis, and metastasis of hepatocellular carcinoma, 8 , 9 and multiple myeloma 10 , 11 . FAM46D, despite its unknown function, is expressed in prostate carcinoma PC-3 cells and in other cancers, including gastric, breast, brain, lung, and gynecological cancers 12 . FAM46B expression was found to be lower in metastatic melanoma cells (United States Patent US 7615349 B2) and serves as a potential marker for multiple myeloma 13 and refractory lupus nephritis 14 .…”

Section: Introductionmentioning

confidence: 99%

FAM46B inhibits cell proliferation and cell cycle progression in prostate cancer through ubiquitination of β-catenin

Tao

Liu

et al. 2018

Exp Mol Med

View full text Add to dashboard Cite

FAM46B is a member of the family with sequence similarity 46. Little is known about the expression and functional role(s) of FAM46B in prostate cancer (PC). In this study, the expression of FAM46B expression in The Cancer Genome Atlas, GSE55945, and an independent hospital database was measured by bioinformatics and real-time PCR analysis. After PC cells were transfected with siRNA or a recombinant vector in the absence or presence of a β-catenin signaling inhibitor (XAV-939), the expression levels of FAM46B, C-myc, Cyclin D1, and β-catenin were measured by western blot and real-time PCR. Cell cycle progression and cell proliferation were measured by flow cytometry and the CCK-8 assay. The effects of FAM46B on tumor growth and protein expression in nude mice with PC tumor xenografts were also measured. Our results showed that FAM46B was downregulated but that β-catenin was upregulated in patients with PC. FAM46B silencing promoted cell proliferation and cell cycle progression in PC, which were abrogated by XAV-939. Moreover, FAM46B overexpression inhibited PC cell cycle progression and cell proliferation in vitro and tumor growth in vivo. FAM46B silencing promoted β-catenin protein expression through the inhibition of β-catenin ubiquitination. Our data clearly show that FAM46B inhibits cell proliferation and cell cycle progression in PC through ubiquitination of β-catenin.

show abstract

Expression Analysis of Cancer-Testis Genes in Prostate Cancer Reveals Candidates for Immunotherapy

Cited by 8 publications

References 74 publications

High Expression of KIF22/Kinesin-Like DNA Binding Protein (Kid) as a Poor Prognostic Factor in Prostate Cancer Patients

High Expression of KIF22/Kinesin-Like DNA Binding Protein (Kid) as a Poor Prognostic Factor in Prostate Cancer Patients

Identification of a Cancer Testis Antigen-Associated Six-Gene Signature in Lung Adenocarcinoma for the Prediction of Survival and Response to Immune-Checkpoint Inhibitors

FAM46B inhibits cell proliferation and cell cycle progression in prostate cancer through ubiquitination of β-catenin

Contact Info

Product

Resources

About